Pharmaceutical Investment Opportunities in Asia: Risk/Reward Analysis
Geographic diversification may be a favourable strategy for multinational pharmaceutical companies, but it is vital that firms recognise both the rewards and the risks present in a market, whether developed or emerging. BMI's Risk/Rewards Ratings (RRR) tool, provides a globally comparative and numerically based assessment of a market's attractiveness, was established to address this. In BMI's Q413 RRRs, the Asia Pacific region scores 53 out of 100, below Western Europe (67), but compares favourably against Americas (51), Central and Eastern Europe (52) and Middle East and Africa (42) regions. The indicators used to assess the attractiveness of a pharmaceutical market are now visible, improving the transparency of the rating system and enabling the identification of regional or group outperformers across single indicators.
Download this free whitepaper now for more.